MARKET

NPCE

NPCE

NeuroPace Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.26
-0.15
-1.59%
After Hours: 9.26 0 0.00% 16:01 01/21 EST
OPEN
9.24
PREV CLOSE
9.41
HIGH
9.36
LOW
8.74
VOLUME
36.84K
TURNOVER
--
52 WEEK HIGH
27.38
52 WEEK LOW
8.29
MARKET CAP
225.15M
P/E (TTM)
-8.9107
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 01/12 13:30
NeuroPace forecasts prelim Q4 revenue of $11M
NeuroPace (NPCE +6.7%) expects prelim. Q4 unaudited revenue of ~$11M, up 2% from $10.8M in Q4 2020. Prelim. unaudited 2021 revenue is expected to be ~$45.2M, up 10% from $41.1M in 2020.
Seekingalpha · 01/11 21:10
BRIEF-Neuropace Announces Preliminary Unaudited Q4 And Full-Year 2021 Revenue
reuters.com · 01/11 21:10
50 Biggest Movers From Yesterday
Gainers
Benzinga · 11/30/2021 09:45
Soleus Capital Management, L.P. Buys DICE Therapeutics Inc, United Therapeutics Corp, Flexion ...
GuruFocus News · 11/15/2021 21:38
NeurPace falls 20% after quarterly results miss estimates
Shares of NeuroPace (NPCE -18.0%) are down after the company posted Q3 2021 earnings after the bell yesterday that missed on both EPS and revenue estimates. Revenue fell 19% year
Seekingalpha · 11/11/2021 17:55
--Wells Fargo Adjusts Price Target on NeuroPace to $20 From $28, Reiterates Overweight Rating
MT Newswires · 11/11/2021 08:20
BRIEF-Neuropace Receives IDE Approval To Initiate NAUTILUS Pivotal Study Of Its RNS System
reuters.com · 11/10/2021 21:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NPCE. Analyze the recent business situations of NeuroPace Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
40.00%Buy
0.00%Hold
20.00%Under-perform
0.00%Sell
Analyst Price Target
The average NPCE stock price target is 21.20 with a high estimate of 30.00 and a low estimate of 12.00.
High30.00
Average21.20
Low12.00
Current 9.26
EPS
Actual
Estimate
-26.18-19.64-13.09-6.55
    0
Q1 2019
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 40
Institutional Holdings: 11.67M
% Owned: 48.01%
Shares Outstanding: 24.31M
TypeInstitutionsShares
Increased
15
566.35K
New
4
732.29K
Decreased
12
135.44K
Sold Out
7
337.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.18%
Healthcare Equipment & Supplies
-1.50%
Key Executives
Chairman/Director
Frank Fischer
President/Chief Executive Officer
Michael Favet
Chief Financial Officer/Vice President - Finance/Vice President - Administration/Primary Contact
Rebecca Kuhn
Vice President/Director of Sales
Mark Saxton
Vice President/Director of Marketing
Chi Nguyen
Vice President
Isabella Abati
Vice President
Cairn Seale
Vice President
Dylan St. John
Vice President
Irene Thomas
General Counsel/Secretary
Irina Ridley
Other
Martha Morrell
Director
Lisa Andrade
Director
Vince Burgess
Independent Director
Greg Garfield
Independent Director
Rakhi Kumar
Independent Director
Joseph Lacob
Independent Director
Renee Ryan
No Data
About NPCE
NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and allows clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. RNS System includes RNS neurostimulator, cortical strip leads, depth leads, patient remote monitor, as well as other implantable and non-implantable accessories.

Webull offers kinds of Neuropace Inc stock information, including NASDAQ:NPCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NPCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NPCE stock methods without spending real money on the virtual paper trading platform.